Generated by AI
DBV Technologies S.A. Sponsored ADR is a France-based biopharmaceutical company focused on epicutaneous immunotherapy, a skin-based approach designed to deliver biologically active compounds through intact skin. The company’s core platform, Viaskin, supports the development of patch-based therapies for food allergies and other immune-mediated conditions. DBV Technologies works at the intersection of immunology and advanced drug delivery, with products and programs centered on non-invasive treatment methods for patients with allergic diseases. Its sponsored ADR gives investors U.S. market access to the company’s ordinary shares while representing the underlying business in the global healthcare sector. The company is headquartered in Châtillon, France, and remains focused on research, development, and commercialization efforts within specialty biopharmaceuticals.
WebsiteBAtiment IRO
Châtillon, 92320
France
The latest articles about DBVT.
Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a late-stage biopharmaceutical company, today announced the company will participate at the following investor conferences in November: Guggenheim Securities 3rd Annual Healthcare Innovation Conference – November 9, 2026Format: Fireside ChatTime: 8:00 am ETLocation: Boston, MA 2026 LifeSci
Summary of Dec 18's posts. Generated by AI.
Summary of Dec 17's posts. Generated by AI.
Summary of Dec 17's posts. Generated by AI.
Summary of Dec 17's posts. Generated by AI.
Investors talking about DBVT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.